Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
Tema
Enfermedad de Parkinson
2534 ARTíCULOS , VIENDO DEL 196 AL 210
Motor outcomes during hospitalization in Parkinson's disease patients: a prospective study.
Gerlach OH, Broen MP, Weber WE.
Parkinsonism Relat Disord. 2013 Aug;19(8):737-41. doi: 10.1016/j.parkreldis.2013.04.017.
0
0
0
Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease.
Böttcher T, Rolfs A, Meyer B, Grossmann A, Berg D, Kropp P, Benecke R, Walter U.
J Neurol. 2013 Oct;260(10):2523-31. doi: 10.1007/s00415-013-7011-2.
0
0
0
Gutiérrez-Valdez AL, García-Ruiz R, Anaya-Martínez V, Torres-Esquivel C, Espinosa-Villanueva J, Reynoso-Erazo L, Tron-Alvarez R, Aley-Medina P, Sánchez-Betancourt J, Montiel-Flores E, Avila-Costa MR.
Behav Pharmacol. 2013 Dec;24(8):640-52. doi: 10.1097/FBP.0000000000000004.
0
0
0
Pienaar IS, Elson JL, Racca C, Nelson G, Turnbull DM, Morris CM.
Am J Pathol. 2013 Dec;183(6):1826-40. doi: 10.1016/j.ajpath.2013.09.002.
0
0
0
Malignant deep brain stimulation-withdrawal syndrome in a patient with Parkinson's disease.
Neuneier J, Barbe MT, Dohmen C, Maarouf M, Wirths J, Fink GR, Timmermann L.
Mov Disord. 2013 Oct;28(12):1640-1. doi: 10.1002/mds.25494. No abstract available.
0
0
0
A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.
Wright JW, Kawas LH, Harding JW.
Front Endocrinol (Lausanne). 2013 Oct 25;4:158. doi: 10.3389/fendo.2013.00158. Review.
0
0
0
Nullity of GSTT1/GSTM1 related to pesticides is associated with Parkinson's disease.
Pinhel MA, Sado CL, Longo Gdos S, Gregório ML, Amorim GS, Florim GM, Mazeti CM, Martins DP, Oliveira Fde N, Nakazone MA, Tognola WA, Souza DR.
Arq Neuropsiquiatr. 2013 Aug;71(8):527-32. doi: 10.1590/0004-282X20130076.
0
0
0
Survey reveals discrimination faced by individuals with Parkinson's.
Blakemore S.
Nurs Older People. 2013 Jun;25(5):7. No abstract available.
0
0
0
Soreq L, Bergman H, Israel Z, Soreq H.
CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1086-93. Review.
0
0
0
[Epidemiology of Parkinson's disease].
Katunina EA, Bezdolny YN.
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(12):81-8. Russian. No abstract available.
0
0
0
Foveal vision is impaired in Parkinson's disease.
Bodis-Wollner I.
Parkinsonism Relat Disord. 2013 Jan;19(1):1-14. doi: 10.1016/j.parkreldis.2012.07.012. Review.
0
0
0
Anandhan A, Essa MM, Manivasagam T.
Neurotox Res. 2013 Feb;23(2):166-73. doi: 10.1007/s12640-012-9332-9.
0
0
0
1-Hz repetitive transcranial magnetic stimulation and diphasic dyskinesia in Parkinson's disease.
Filipović SR, Bhatia KP, Rothwell JC.
Mov Disord. 2013 Feb;28(2):245-6. doi: 10.1002/mds.25261. No abstract available.
0
0
0
Is there room for new non-dopaminergic treatments in Parkinson's disease?
Pilleri M, Koutsikos K, Antonini A.
J Neural Transm (Vienna). 2013 Feb;120(2):349-52. doi: 10.1007/s00702-012-0947-z.
0
0
0
The pathophysiology of impulse control disorders in Parkinson disease.
Balarajah S, Cavanna AE.
Behav Neurol. 2013;26(4):237-44. doi: 10.3233/BEN-2012-120266. Review.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
